NL
DE
4 July 2019
Ronald van Rij (1972, Hellevoetsluis) received his Master’s in Bioprocess Technology at Wageningen University in 1996 and from 1997-2002 worked as a researcher at Sanquin Research (previously the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service) in Amsterdam. In 2002 he obtained his PhD (cum laude) at the University of Amsterdam on research into Chemokine receptors in HIV-1 infection and AIDS pathogenesis.
He then worked for four years as a postdoctoral researcher at the University of California San Francisco (USA). Back in the Netherlands, he became a researcher at the Hubrecht Institute for Developmental Biology and Stem Cell Research. In 2008 Van Rij came to Radboud university medical center and the Radboud Institute for Molecular Life Sciences (RIMLS), where he set up a new research group with the help of a Hypatia Tenure Track Grant, a Radboudumc programme in which excellent researchers develop to become leaders within their academic fields.
Since 2012, he has been head of the Experimental Virology Laboratory of the Medical Microbiology Department. In 2018 he was a visiting professor at the University of Pavia (Italy). In addition to his research, Van Rij provides virology, innate immunity and RNA biology education in various BSc and MSc programmes.
Van Rij received a large number of grants and scholarships for his work, including an ERC Consolidator Grant (2013) and a grant from the Human Frontiers Science Program (2017) for research into the antiviral immune system of mosquitoes that contain the Dengue and Zika viruses transfer. The antiviral immune system of the mosquito is a critical determining factor for the transmission of viruses. His VICI Grant (2017) is intended for research into the role of small RNAs in gene regulation and mosquito antiviral defences.
Ronald van Rij, theme Infectious diseases and global health, has been appointed Professor of Experimental Virology at Radboud University / Radboud university medical center with effect from 1 July 2019.
Ronald van Rij (1972, Hellevoetsluis) received his Master’s in Bioprocess Technology at Wageningen University in 1996 and from 1997-2002 worked as a researcher at Sanquin Research (previously the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service) in Amsterdam. In 2002 he obtained his PhD (cum laude) at the University of Amsterdam on research into Chemokine receptors in HIV-1 infection and AIDS pathogenesis.
He then worked for four years as a postdoctoral researcher at the University of California San Francisco (USA). Back in the Netherlands, he became a researcher at the Hubrecht Institute for Developmental Biology and Stem Cell Research. In 2008 Van Rij came to Radboud university medical center and the Radboud Institute for Molecular Life Sciences (RIMLS), where he set up a new research group with the help of a Hypatia Tenure Track Grant, a Radboudumc programme in which excellent researchers develop to become leaders within their academic fields.
Since 2012, he has been head of the Experimental Virology Laboratory of the Medical Microbiology Department. In 2018 he was a visiting professor at the University of Pavia (Italy). In addition to his research, Van Rij provides virology, innate immunity and RNA biology education in various BSc and MSc programmes.
Van Rij received a large number of grants and scholarships for his work, including an ERC Consolidator Grant (2013) and a grant from the Human Frontiers Science Program (2017) for research into the antiviral immune system of mosquitoes that contain the Dengue and Zika viruses transfer. The antiviral immune system of the mosquito is a critical determining factor for the transmission of viruses. His VICI Grant (2017) is intended for research into the role of small RNAs in gene regulation and mosquito antiviral defences.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Rebecca Halbach receives idea generator grant to fight mosquito transmitted viruses
8 July 2020 Rebecca Halbach and Pascal Miesen have investigated in a collaborative project whether the treatment of mosquitoes with antiviral drugs can prevent the transmission of mosquito-transmitted viral diseases. read more
Invasive fungal infections in influenza and COVID-19
8 July 2020 The Aspergillus fungus is found in the lungs of many COVID patients. A parallel occurs with influenza patients, who often develop a serious fungal infection. Although such a serious fungal infection seems to occur less frequently in COVID-patients, alertness remains necessary, read more
First clinical trial with genetically modified malaria vaccine completed
22 May 2020 In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection. read more
New step in the development of a vaccine against malaria
22 May 2020 A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine. read more
Stuttering DNA orchestrates the start of the mosquito’s life
9 April 2020 A certain type of junk DNA that is found in mosquitoes and which repeats itself dozens of times, known as ‘satellite DNA’, has now been shown to play an essential role in the early development of mosquito embryos. Ronald van Rij and colleagues published their findings in Nature. read more
